Health Care · In Vitro & In Vivo Diagnostic Substances · Nasdaq · CIK 1642380 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $4.37Day −5.21%Mkt cap $141M1Y +60.1%Off 52W high −48.6%Vol (1Y) 104.8%
Daily closing price, split-adjusted to the current basis; 1.1y shown of 269 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest3.9% of sh out |
| Days to cover4.3d |
| 13F net flow (QoQ)+2.29% |
| Top-10 13F concentration96.3% |
| Next report (est.)2026-08-12 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$1.9M |
| Earnings (TTM)-$47.8M |
| Net margin−1238.5% |
| Sales growth 3Y61.8% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−41.7% |
| 1Y+60.1% |
| Since incept. (ann.)+33.9% |
Total return through 2026-07-29 · series begins 2025-06-18. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)104.8% |
| Ann. volatility (3Y)107.4% |
| Sharpe (1Y)0.97 |
| Sharpe (3Y)0.81 |
| Max drawdown (1Y)−69.9% |
| Max drawdown (3Y)−69.9% |
| Beta (3Y vs SPY)5.26 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| BROADWOOD CAPITAL INC | 11.9M | $39M | 36.95% | +4.6% |
| AWM Investment Company, Inc. | 2.8M | $9M | 8.69% | −0.3% |
| PURA VIDA INVESTMENTS, LLC | 947,134 | $3M | 2.93% | +0.0% |
| Alyeska Investment Group, L.P. | 840,777 | $3M | 2.60% | new |
| VANGUARD CAPITAL MANAGEMENT LLC | 537,161 | $2M | 1.66% | new |
| HEIGHTS CAPITAL MANAGEMENT, INC | 392,545 | $1M | 1.22% | new |
| GEODE CAPITAL MANAGEMENT, LLC | 262,053 | $860,170 | 0.81% | +13.5% |
| FNY Investment Advisers, LLC | 247,421 | $811,000 | 0.77% | +509.7% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-13 | −$0.12 | — | $32,000 | −98.5% |
| 2025-12-31 | 2026-03-26 | — | — | $1.1M | −23.4% |
| 2025-09-30 | 2025-11-10 | −$0.34 | — | $260,000 | +126.1% |
| 2025-06-30 | 2025-08-11 | −$0.30 | — | $518,000 | +398.1% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-12 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
US 99% · Europe 1%
geographic · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
